Prospective evaluation of corrected QT intervals and arrhythmias after exposure to epirubicin, cyclophosphamide, and 5-fluorouracil in women with breast cancer

Annals of Oncology

Volumn 23, Issue 3, 2012, Pages 743-747

  Kitagawa, K ^a   Kawada, K ^a   Morita, S ^a   Inada, M ^a   Mitsuma, A ^a   Sawaki, M ^a   Iino, S ^b   Inden, Y ^b   Murohara, T ^b   Imai, T ^c   Ando, Y ^a  

^a NAGOYA UNIVERSITY HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Breast cancer; Cardiovascular toxicity; Chemotherapy; Drug induced QT prolongation

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL;

ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEBRILE NEUTROPENIA; FEMALE; GENETIC ASSOCIATION; HEART ARRHYTHMIA; HEART LEFT VENTRICLE FAILURE; HUMAN; INFECTION; LIVER TOXICITY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; QT INTERVAL; QT PROLONGATION; SINGLE NUCLEOTIDE POLYMORPHISM; SUPRAVENTRICULAR PREMATURE BEAT;

EID: 84857592984     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr296     Document Type: Article

References (14)

1. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 2002; 13: 699-709.
2. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004; 350: 1013-1022.
3. Roberts R. Genomics and cardiac arrhythmias. J Am Coll Cardiol 2006; 47: 9-21.
4. Wortman JE, Lucas VS Jr, Schuster E et al. Sudden death during doxorubicin administration. Cancer 1979; 44: 1588-1591.
5. Schwartz CL, Hobbie WL, Truesdell S et al. Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer. J Clin Oncol 1993; 11: 1906-1910.
6. Martin M, Rodriguez-Lescure A, Ruiz A et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst 2008; 100: 805-814.
7. Nousiainen T, Vanninen E, Rantala A et al. QT dispersion and late potentials during doxorubicin therapy for non-Hodgkin's lymphoma. J Intern Med 1999; 245: 359-364.
8. Nakamae H, Tsumura K, Hino M et al. QT dispersion as a predictor of acute heart failure after high-dose cyclophosphamide. Lancet 2000; 355: 805-806.
9. Oztop I, Gencer M, Okan T et al. Evaluation of cardiotoxicity of a combined bolus plus infusional 5-fluorouracil/folinic acid treatment by echocardiography, plasma troponin I level, QT interval and dispersion in patients with gastrointestinal system cancers. Jpn J Clin Oncol 2004; 34: 262-268.
10. Galetta F, Franzoni F, Cervetti G et al. Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients. Biomed Pharmacother 2005; 59: 541-544.
11. Pfeufer A, Jalilzadeh S, Perz S et al. Common variants in myocardial ion channel genes modify the QT interval in the general population: results from the KORA study. Circ Res 2005; 96: 693-701.
12. Newton-Cheh C, Guo CY, Larson MG et al. Common genetic variation in KCNH2 is associated with QT interval duration: the Framingham Heart Study. Circulation 2007; 116: 1128-1136.
13. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97: 2869-2879.
14. Ducroq J, Moha ou Maati H, Guilbot S et al. Dexrazoxane protects the heart from acute doxorubicin-induced QT prolongation: a key role for I(Ks). Br J Pharmacol 2010; 159: 93-101.